Bio-Techne (TECH) earnings call transcripts

Management framed the quarter as a temporary timing- and biotech-driven setback, while stressing improving academic, China and pharma trends and cautious fiscal 2027 optimism.

Management framed the quarter as an improving underlying business obscured by temporary cell-therapy order timing and uneven end-market recovery.

Management framed Q1 as a disciplined execution quarter, with near-term cell-therapy timing masking improving underlying demand and continued confidence in low-single-digit annual growth.